title: Antiplatelet and anticoagulation therapy for acute coronary syndromes.
abstract: The past 2 decades have witnessed the introduction and demise of several different antithrombotic medications for acute coronary syndromes. Part of the assessment of these compounds has been their effect on thrombotic events relative to the degree of increase in bleeding events. This review will outline the data supporting various antiplatelet and anticoagulant therapies and their combinations in patients with acute coronary syndromes and related disorders in both the acute and chronic phases of therapy.
authors.affiliation: From the Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.L.B.); Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY (J.-S.H.); Department of Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.); and Stanford University, CA (R.A.H.). dlbhattmd@post.harvard.edu.
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
authors.affiliation: From the Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.L.B.); Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY (J.-S.H.); Department of Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.); and Stanford University, CA (R.A.H.).
authors.forename: Jean-Sébastien
authors.initials: JS
authors.lastname: Hulot
authors.affiliation: From the Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.L.B.); Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY (J.-S.H.); Department of Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.); and Stanford University, CA (R.A.H.).
authors.forename: David J
authors.initials: DJ
authors.lastname: Moliterno
authors.affiliation: From the Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.L.B.); Icahn School of Medicine at Mount Sinai, Cardiovascular Research Institute, New York, NY (J.-S.H.); Department of Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.); and Stanford University, CA (R.A.H.).
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors
keywords: acute coronary syndrome; hemorrhage; myocardial infarction